MedTrace Logo

Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women

NCT05853718 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-09-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.

Conditions

Interventions

DRUG

Tenofovir Alafenamide Tablets

Take 25mg TAF daily from week 28-32 of gestation until delivery

Sponsors & Collaborators

  • First People's Hospital of Hangzhou

    lead OTHER

Principal Investigators

  • Zhiyuan Ma, PhD · First People's Hospital of Hangzhou

  • Siying Li, MD · First People's Hospital of Hangzhou

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-06
Primary Completion
2025-12-30
Completion
2025-12-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05853718 on ClinicalTrials.gov